Literature DB >> 21670474

Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment.

Maike Schmitz1, Petra Breithaupt, Nastassja Scheidegger, Gunnar Cario, Laura Bonapace, Barbara Meissner, Paulina Mirkowska, Joelle Tchinda, Felix K Niggli, Martin Stanulla, Martin Schrappe, Andre Schrauder, Beat C Bornhauser, Jean-Pierre Bourquin.   

Abstract

Clonal evolution of the leukemogenic compartment may contribute to alter the therapeutic response in acute lymphoblastic leukemia (ALL). Using xenotransplantation of primary leukemia cells, we evaluated the phenotypic and genetic composition of de novo resistant very high risk precursor B-cell ALL, a subgroup defined by the persistence of minimal residual disease despite intensive chemotherapy. Analysis of copy number alterations (CNAs) showed that the xenografted leukemia, even when reconstituted from 100 cells, remained highly related to the diagnostic sample, with minor changes in CNAs, mostly deletions, emerging in most cases in the first passage into mice. At the single-cell level, the pattern of monoallelic and biallelic deletions of the CDKN2A locus revealed distinct leukemia subpopulations, which were reproducibly tracked in xenografts. In most very high risk ALL cases, the predominant diagnostic clones were reconstituted in xenografts, as shown by multiplex polymerase chain reaction analysis of immunoglobulin and T-cell receptor loci. In other cases, the pattern in CNAs and immunoglobulin and T-cell receptor rearrangement was less concordant in xenografts, suggesting the outgrowth of subclones. These results unequivocally demonstrate the existence of clonally closely related but distinct subsets of leukemia initiating cells in ALL, which has important implications for drug development and preclinical disease modeling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670474     DOI: 10.1182/blood-2010-11-320309

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.

Authors:  T N Trahair; R B Lock; R Sutton; K C S Sia; K Evans; J Richmond; T Law; N C Venn; J A Irving; S Moore; E Nievergall; P Dang; S L Heatley; D L White; T Revesz
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483

2.  Functional heterogeneity of genetically defined subclones in acute myeloid leukemia.

Authors:  Jeffery M Klco; David H Spencer; Christopher A Miller; Malachi Griffith; Tamara L Lamprecht; Michelle O'Laughlin; Catrina Fronick; Vincent Magrini; Ryan T Demeter; Robert S Fulton; William C Eades; Daniel C Link; Timothy A Graubert; Matthew J Walter; Elaine R Mardis; John F Dipersio; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-06       Impact factor: 31.743

3.  Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.

Authors:  David M Barrett; Alix E Seif; Carmine Carpenito; David T Teachey; Jonathan D Fish; Carl H June; Stephan A Grupp; Gregor S D Reid
Journal:  Blood       Date:  2011-08-19       Impact factor: 22.113

Review 4.  Epidemiology and biology of relapse after stem cell transplantation.

Authors:  Mary Horowitz; Hans Schreiber; Alex Elder; Olaf Heidenreich; Josef Vormoor; Christina Toffalori; Luca Vago; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2018-04-18       Impact factor: 5.483

5.  Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.

Authors:  Viktoras Frismantas; Maria Pamela Dobay; Anna Rinaldi; Joelle Tchinda; Samuel H Dunn; Joachim Kunz; Paulina Richter-Pechanska; Blerim Marovca; Orrin Pail; Silvia Jenni; Ernesto Diaz-Flores; Bill H Chang; Timothy J Brown; Robert H Collins; Sebastian Uhrig; Gnana P Balasubramanian; Obul R Bandapalli; Salome Higi; Sabrina Eugster; Pamela Voegeli; Mauro Delorenzi; Gunnar Cario; Mignon L Loh; Martin Schrappe; Martin Stanulla; Andreas E Kulozik; Martina U Muckenthaler; Vaskar Saha; Julie A Irving; Roland Meisel; Thomas Radimerski; Arend Von Stackelberg; Cornelia Eckert; Jeffrey W Tyner; Peter Horvath; Beat C Bornhauser; Jean-Pierre Bourquin
Journal:  Blood       Date:  2017-01-25       Impact factor: 22.113

Review 6.  Clonal evolution in cancer.

Authors:  Mel Greaves; Carlo C Maley
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

7.  Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts.

Authors:  Santi Suryani; Hernan Carol; Triona Ni Chonghaile; Viktoras Frismantas; Chintanu Sarmah; Laura High; Beat Bornhauser; Mark J Cowley; Barbara Szymanska; Kathryn Evans; Ingrid Boehm; Elise Tonna; Luke Jones; Donya Moradi Manesh; Raushan T Kurmasheva; Catherine Billups; Warren Kaplan; Anthony Letai; Jean-Pierre Bourquin; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2014-07-10       Impact factor: 12.531

8.  CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage.

Authors:  L Slamova; J Starkova; E Fronkova; M Zaliova; L Reznickova; F W van Delft; E Vodickova; J Volejnikova; Z Zemanova; K Polgarova; G Cario; M Figueroa; T Kalina; K Fiser; J P Bourquin; B Bornhauser; M Dworzak; J Zuna; J Trka; J Stary; O Hrusak; E Mejstrikova
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528

9.  CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations.

Authors:  Jawad Francis; Avinash V Dharmadhikari; Sheila N J Sait; George Deeb; Paul K Wallace; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Leuk Lymphoma       Date:  2013-01-03

10.  TNFR2 is required for RIP1-dependent cell death in human leukemia.

Authors:  Júlia Aguadé-Gorgorió; Scott McComb; Cornelia Eckert; Anna Guinot; Blerim Marovca; Caterina Mezzatesta; Silvia Jenni; Liridon Abduli; Martin Schrappe; Maria Pamela Dobay; Martin Stanulla; Arend von Stackelberg; Gunnar Cario; Jean-Pierre Bourquin; Beat C Bornhauser
Journal:  Blood Adv       Date:  2020-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.